High-dose chemotherapy with stem cell transplantation (SCT) is feasible for elderly patients and patients with renal insufficiency. However, the impact of treatment on this patient population is unclear. We evaluated 678 consecutive patients with multiple myeloma who underwent SCT at Mayo Clinic. The complete response rate, time to progression and overall survival was recorded. Patients were stratified according to age (p65 or 465 years) and serum creatinine value at the time of transplantation (p2 or 42 mg/dl). Patient age did not have an effect on any outcome measure. Creatinine level did not affect complete response rate and time to progression, but patients with creatinine levels above 2 mg/ml had a higher day-100 mortality rate and a shorter overall survival rate. Platelet engraftment was also significantly delayed for patients with renal insufficiency. Selected patients over age 65 years may have outcomes identical to that of younger patients. When compared with patients with creatinine levels less than 2 mg/ml, patients with elevated creatinine levels had similar response rates and time to progression, but their overall survival was inferior. Transplantation should be offered to selected patients over age 65 years or selected patients with creatinine elevation.
Introduction
Two prospective randomized studies have unequivocally shown that recipients of high-dose chemotherapy with autologous stem cell transplantation (SCT) have superior survival when compared with patients treated with conventional therapy. 1, 2 In both studies, patients were younger than 65 years. In the Intergroupe Franc¸ais du Mye´lome study, 1 the median serum creatinine level was 1.3 mg/dl, and creatinine had no effect on outcome. In the Medical Research Council of Britain study, 2 19% of patients had creatinine levels greater than 1.7 mg/dl.
Neither study indicated what fraction of patients had persistent creatinine elevation at the time of transplantation; both studies reported creatinine levels only at study enrollment, and many patients may have had reversal of renal insufficiency with the induction therapy.
Controversies exist about the benefits of transplantation for patients with renal failure or age greater than 65 years. In a prospective randomized study of Italian patients, 3 intermediate-dose melphalan improved survival of myeloma patients aged 50-70 years. In a separate analysis of patients aged 65-70 years, intermediate-dose melphalan improved response rate, event-free survival rate and overall survival rate. In contrast, the Group Myelome-Autogreffe researchers found that high-dose therapy for patients aged 55-65 years did not result in improved overall survival when compared with conventional chemotherapy. 4 The IFM-99-06 trial 5 enrolled patients aged 65-75 years and compared patients treated only with melphalan and prednisone with patients who underwent tandem transplantations and received melphalan-100 (melphalan dosage, 100 mg/m 2 ). A third arm of the study examined patients who also received thalidomide. The progressionfree survival was 17.1 and 19 months for patients receiving melphalan-prednisone and patients undergoing transplantation and receiving melphalan-100, respectively. Overall survival times were 30.3 and 38.6 months for the melphalan-prednisone group and the melphalan-100 group, respectively. These studies raised serious questions about establishing a maximal threshold for age and serum creatinine values when selecting patients with multiple myeloma to receive high-dose therapy before undergoing SCT. The purpose of this study is to assess the effects of age and serum creatinine values at the time of transplantation on the overall outcome of patients with multiple myeloma treated at Mayo Clinic.
Materials and methods
Between June 1989 and November 2005, 678 patients with multiple myeloma underwent SCT at Mayo Clinic. We had follow-up data from all patients for at least 9 months. Patient information was captured prospectively in a continuously updated database. No patients were lost to follow-up. All patients provided written informed consent for use of their medical records. Approval of the Mayo Foundation Institutional Review Board was obtained in accordance with federal regulations and the Declaration of Helsinki.
The serum creatinine level used in our analysis was the value measured immediately before SCT; patient age on the day of SCT (day 0) also was recorded. All patients who underwent SCT were included in our analysis. We defined response using the criteria established by Blade et al. 6 A complete response had negative immunofixation findings from serum and urine. A partial response consisted of a 50% reduction of monoclonal proteins in the serum and a 90% decrease in urinary light-chain excretion when compared with pretransplantation levels. Response duration was defined as the time between the day of transplantation and the day when evidence of progression was observed. For patients who did not achieve a response before transplantation, the duration of response was defined as the first recorded response value after transplantation until disease progression was noted. Relapse or progression was defined as a 50% increase in the level of serum M protein or an increase (above the lowest response value recorded previously) in 24-h urine M-protein excretion level. For patients who achieved a complete response, disease progression was defined as detection of M protein by immunofixation, increase in the size of existing bony lesions or soft-tissue plasmacytomas, or new lytic lesions. Bone marrow plasma cell labeling index, cytogenetic findings, b 2 -microglobulin levels and other laboratory variables were assessed before transplantation. The labeling index, a measure of cell kinetics, was determined using bone marrow samples and a slide-based immunofluorescence method. 7 Survival was calculated from transplant day 0. For nominal variables and nonparametric tests, the w 2 and Fisher's exact tests were used to compare differences among the patient groups. The Mann-Whitney test was used to analyze continuous variables. Kaplan-Meier analysis was used to determine time to progression and overall survival. P-values less than 0.05 were considered significant.
Results

Age
Characteristics of the 678 patients who underwent SCT are shown in Table 1 . Patients were stratified by age (p65 years (n ¼ 541) or 465 years (n ¼ 137)). The groups had significant differences in serum creatinine levels, in accordance with an age-related decline in renal clearance. The serum b 2 -microglobulin levels were not significantly different between groups (P ¼ 0.07). The melphalan dose was reduced to 140 mg/m 2 for 15% of patients over 65 years and reduced for only 5% of patients 65 years or younger. Half the patients 65 years or younger who received less than 200 mg/m 2 of melphalan or its equivalent had clinically significant renal insufficiency. Eleven patients who underwent SCT were older than 65 years and had a serum creatinine level greater than 2.0 mg/dl. Figure 1 shows time to progression for the 678 patients (grouped by age). The median time to progression was 17 months overall, and this was not significantly different between the patient groups. Figure 2 shows the effect of age on overall survival after SCT. Both groups had identical median survival periods of 44 months (P ¼ 0.28). The mortality rate at day 100 was 3% for both groups.
We subsequently performed an analysis of patients who received only one therapy regimen before SCT and excluded patients who underwent multiple treatment regimens for cytoreduction before transplantation. In this analysis, 342 patients were 65 years or younger and 99 were older than 65 years. The groups showed no difference in time to progression (median response duration, 19.3 months), and the overall survival was the same for both groups (median, 58 months). Of the 673 patients who were evaluable for a complete response, 226 (34%) achieved a complete response. In the older age group, 55 of 137 (40%) achieved a complete response, and in the younger group, 171 of 571 (30%) had a complete response; the differences were not statistically significant.
Analysis of patients categorized by Durie-Salmon stage, International Staging System (ISS) stage 8 and serum albumin level showed no differences between the groups (Table 1 ). An analysis was performed to assess the effect of age on survival of patients stratified by disease status at the time of transplantation. Although patients who underwent transplantation while the disease was in relapse had a shorter survival than those who were in a plateau phase of the disease (26 vs 61 months), age had no impact on survival. An analysis of patients stratified by unfavorable biologic characteristics was also performed. Patients with chromosome 13 monosomy or partial deletion had a shorter overall survival (18.8 months), but no differences between the older and younger cohorts were observed. Likewise, those with a plasma cell labeling index of 1.0 or higher had an overall survival of 23.8 months, but survival was not significantly different between patients 65 years and younger and patients older than 65 years (Wilcoxon,
In spite of the similar survival curves, toxicity differences were noted among older and younger patients. At our institution, all patients received conditioning and reinfusion as outpatients. Hospitalization was reserved for those with declining performance status, nutritional failure or uncontrolled fever. For younger patients, the median hospital duration was 5 days; for older patients, the median stay was 7.5 days (P ¼ 0.06). Bacteremia was documented in 39% of older patients and 42% of younger patients. Figure 3 shows the survival of patients categorized by melphalan dosage and age. For carefully selected patients, it is possible to (1) administer full-intensity therapy without increasing therapy-related mortality and (2) produce outcomes equivalent to that of younger patients. We could not show a poorer outcome for older patients who received less than full conditioning because the small number of patients (n ¼ 26) meant that the power to detect differences was limited. Table 2 shows the patient characteristics stratified by serum creatinine level (p2.0 mg/ml (n ¼ 637) or 42.0 mg/ml (n ¼ 40)). (One patient did not have a creatinine measurement before SCT.) For a high proportion of patients, renal insufficiency was reversed after induction therapy, and only 6% of the entire cohort had impaired renal function on the day of transplantation. Patients with poor renal function had significantly higher levels of serum b 2 -microglobulin (serum b 2 -microglobulin is renally excreted). They also had lower concentrations of serum M component and higher levels of protein loss in the urine. These differences underscored the fact that most of these patients had presumed myeloma cast nephropathy, which occurs frequently in light-chain myeloma. Conditioning intensity was reduced below the standard (200 mg/m 2 ) melphalan dose for 56% of patients with serum creatinine levels greater than 2 mg/ml, but dosage was reduced for only 4% of patients with serum creatinine 2 mg/ml or lower. For 14 of these patients, the dose reduction was related to age greater than 70 years (these patients have lower tolerance of highdose chemotherapy).
Renal function
Impairment of renal function had no impact on time to progression (17 months) for either group (Figure 4) . However, patients with renal insufficiency had a substantially higher day-100 mortality rate (13%) than those patients with normal renal function (3%). Patients with impaired renal function also had significantly shorter survival times (median, 31 months) than those patients with normal renal function (median, 47 months) ( Figure 5 ). Of the 40 patients with impaired renal function, none survived 5 years after SCT. The low survival suggested that patients with impaired renal function had a limited ability to respond to salvage chemotherapy after disease progression.
When analysis was limited to patients who received only one type of therapy before transplantation, the median time to progression was 19.3 months for all. Overall survival was significantly better for patients with normal renal function (61 months) than the patients with impaired function (27 months), and the day-100 mortality rate was 14 and 2% for patients with impaired and normal renal function, respectively. Of the patients evaluable for a complete response, the response rate was 34% (218 of 638) for patients with normal renal function and 22% (eight of 37) for patients with impaired renal function. The difference was not statistically significant.
Analysis of patients categorized by Durie-Salmon stage and ISS stage showed significant differences among groups (Table 2) . Because the Durie-Salmon criteria for stages A and B are based on serum creatinine levels, virtually all patients with normal renal function were grouped into stages IIA and IIIA, and all patients with renal insufficiency were grouped into stages IIB and IIIB. The ISS stage is weighted heavily by the serum b 2 -microglobulin level (b 2 -microglobulin is excreted renally). Almost all patients with renal insufficiency had elevated serum b 2 -microglobulin levels. Consequently, none of the patients with creatinine levels greater than 2.0 mg/dl were characterized as ISS stage 1, and 80% were characterized as ISS stage 3. The Cox proportional hazards regression model showed that the effect of ISS stage on survival was significant (P ¼ 0.008) and eliminated creatinine from the predictive model, consistent with the original ISS classification scheme. 9 We also assessed the survival of patients with renal insufficiency on the basis of disease status at the time of transplantation. Because our cohort had only 40 patients with renal insufficiency, after stratification by disease status, we had sufficient data for survival analysis only for the group of patients in a plateau phase at the time of transplantation. In this subset, survival was significantly shorter for patients with creatinine levels exceeding 2.0 mg/ dl (40 vs 61 months for patients with creatinine levels o2.0 mg/dl) (P ¼ 0.02).
Survival analysis of patients with unfavorable biologic characteristics (patients with renal failure, chromosome 13 monosomy, or partial deletion) could not be performed because of insufficient data. Those with a plasma cell labeling index of 1.0 or higher had an overall survival of 24 months if creatinine levels were 2.0 mg/dl or lower, or 15.5 months if creatinine levels exceeded 2.0 mg/dl (Wilcoxon, P ¼ 0.05). Major toxicity differences were noted among patients stratified by renal function. For patients with creatinine levels 2.0 mg/dl or lower, the median hospital duration was 6 days. For patients with creatinine levels exceeding 2.0 mg/dl, median hospitalization was 13 days (Po0.001). Bacteremia was documented in 40% of patients with creatinine levels 2.0 mg/dl or lower and in 61% of patients with creatinine levels exceeding 2.0 mg/dl (P ¼ 0.02). Figure 6 shows the survival of patients categorized by therapy intensity and serum creatinine levels. It illustrates the need to reduce the melphalan dose when the creatinine level exceeds 2.0 mg/dl. Most of the early mortality of The median overall survival was 31 or 47 months for patients with impaired or normal renal function, respectively. The day-100 mortality rate is shown by the asterisk (3%) and the dagger (13%). Ticks indicate censored data.
patients with renal insufficiency occurred in the fullintensity group (day-100 mortality, 25%; median survival, 15.5 months). The survival of patients with renal insufficiency who received reduced-dose melphalan was 40.2 months; this was only slightly shorter than the 49-month median survival of full-intensity patients with normal renal function. Among the 11 patients who were older than 65 years and had a creatinine level greater than 2.0 gm/dl, only three have died to date (1.3, 3.6 and 29.1 months after transplantation). We have insufficient follow-up data to make reliable survival estimates.
Engraftment
Patients 65 years and younger had neutrophil engraftment at 13 days, had 50 000 platelets/ml at 15 days and were infused with 5.1 Â 10 6 CD34 þ cells/kg. Patients older than 65 years had neutrophil engraftment at 12 days (P ¼ NS), had 50 000 platelets/ml at 17 days (P ¼ NS) and were infused with 4.8 Â 10 6 CD34 þ cells/kg (P ¼ 0.002). When grouped by renal function, patients with creatinine levels 2 mg/dl or lower had a neutrophil count of 500/ml at 13 days, a platelet count of 50 000/ml at 15 days and had 5.05 Â 10 6 CD34 þ cells infused. Patients with creatinine levels above 2 mg/dl had a neutrophil count of 500/ml at 12 days (P ¼ NS), a platelet count of 50 000/ml at 18.5 days (P ¼ 0.002) and were infused with 4.66 Â 10 6
CD34
þ cells/kg (P ¼ NS). The median duration of hospitalization was 5 days for patients 65 years or younger and 7 days for patients 465 years. This difference was not significant (P ¼ 0.08). However, for patients with renal insufficiency, the median hospitalization time was 13 days. Patients without renal insufficiency were hospitalized for a median of 6 days; this difference was significant (Po0.001).
Discussion
Evidence-based recommendations for management of older patients or patients with renal insufficiency are lacking.
Royal Marsden researchers reviewed their experience with 17 patients aged 65-74 years, and 17 younger, matchedcontrol patients (median age, 55 years). 10 Conditioning was well tolerated by both groups, and engraftment times and treatment-related mortality rates were similar. Median overall survival of the older cohort was 3.59 years. Because that was not significantly different from the overall survival of control subjects, the data suggested that patients aged 65 years or older should not be excluded from autologous transplantation. In a case-matched analysis of older and younger patients, no differences in engraftment kinetics, extramedullary toxicities or event-free or overall survival were observed. Age was not identified as an adverse parameter in multivariate analysis. 11 The largest study of patients older than 70 years was performed by researchers at the Myeloma and Transplantation Research Center of the University of Arkansas for Medical Sciences; they analyzed data from 34 newly diagnosed patients and 36 refractory patients (median age, 72 years). 12 Half the patients were mobilized with chemotherapy and filgrastim, and half received only filgrastim. All had excellent stem cell yields, although the chemotherapy-mobilized group had greater yields. Four of the first 25 patients who underwent transplantation died after conditioning with melphalan-200, and the dose for the remaining 21 patients was reduced subsequently to 140 mg/m 2 . After dose reduction, the engraftment time and complete response rate were similar to those of younger patients. The 3-year event-free and overall survival rates were 20 and 31%, respectively. For elderly patients, treatment with melphalan-140 was less toxic and equally efficacious as treatment with melphalan-200.
The Autologous Blood and Bone Marrow Transplant Registry researchers compared the outcomes of 110 patients older than 60 years (median age, 63 years) with those of 382 younger patients (median age, 52 years). 13 The groups were matched, except for b 2 -microglobulin levels and the number of lytic lesions. For older patients, the day-100 mortality rate was 6%, and the 1-year treatmentrelated mortality rate was 9%. For younger patients, the day-100 mortality rate was 5% and the 1-year treatmentrelated mortality rate was 8%. The relapse rate, progression-free survival time and overall survival rate of the two groups were similar. The best results were observed after early transplantation.
In a multicenter study, 194 patients, aged 50-70 years, were randomized at diagnosis to receive six courses of melphalan and prednisone or tandem courses of melphalan-100 and stem cell support. 3 The response rate was higher after melphalan-100 treatment. Three years after therapy, patients who received melphalan-100 had an event-free survival rate of 37% (16% for the melphalanprednisone group), and the overall survival rate was 77% (62% for the melphalan-prednisone group). For the subgroup of patients aged 65-70 years, the event-free survival rate improved from 18 to 31%, and overall survival at 3 years rose from 58 to 73%. Older patients had a median overall survival of 37. survival rate and overall survival rate for all patients older than 50 years (including those aged 65-70 years). It is, therefore, possible to select a group of elderly patients whose outcome will be similar to that of younger patients. This highly selected group of patients could be expected to have similar outcomes and low treatment-related mortality rates. The use of autologous SCT for patients with myeloma and renal insufficiency has been questioned. In a report of patients with moderate-to-severe renal insufficiency, 14 four underwent SCT as frontline therapy and two were treated at relapse. The melphalan dose was reduced to 80 mg/m 2 for two and combined with busulfan (12 mg/kg) for four. Engraftment was prompt. No grade 3 or 4 infectious complications occurred. Five of the six responded to therapy, and three were progression free at 2, 15, and 26 months after transplantation.
Researchers at the Myeloma and Transplantation Research Center of the University of Arkansas for Medical Sciences described 81 myeloma patients who had renal failure before transplantation. 15 In total, 60 patients underwent transplantation with melphalan-200. Excessive toxicity resulted in a reduction of the melphalan dose to 140 mg/m 2 for the remaining 21. The treatment-related mortality rate after the first SCT was 6%. Neutrophil engraftment and platelet engraftment occurred at 11 and 41 days, respectively. The complete response rate was 26% after the first SCT; at a median follow-up of 31 months, 30 of 81 had died. The 3-year event-free and overall survival rates were 48 and 55%, respectively. Renal failure did not affect stem cell collection or engraftment, and the degree of toxicity was acceptable. A subsequent report from the same group described 59 patients on dialysis. 16 The 5-year event-free and overall survival rates were 24 and 36%, respectively. Of 54 evaluable patients, 24% became dialysis independent. The data suggested that clinically significant renal failure may be reversed if transplantation is performed early in the disease course.
A report compared 137 patients with normal renal function at diagnosis and transplantation with 29 patients with renal failure. 17 Researchers found that 10 of 29 patients with renal failure at diagnosis had post-transplantation normalization of renal function, but they had longer hospitalization periods, greater use of blood products and a higher number of infections. The treatment-related mortality rate was 17% for the patients with renal impairment at the time of transplantation. Four dialysis-dependent patients died within the first 100 days.
In our cohort, the time to progression was identical, but the treatment-related mortality rate was clearly higher for patients with renal insufficiency, and the overall survival time for our patients was shorter. Nonetheless, it is possible to select a cohort of patients with renal insufficiency which, with reduced-dose conditioning, may safely undergo transplantation and have an initial response duration identical to that of patients with normal renal function at the time of transplantation. The Spanish Registry for Transplant in Multiple Myeloma described 14 patients with abnormal renal function at transplantation. 18 Patients with renal insufficiency had a significantly higher number of adverse prognostic factors. The patients showed no difference in platelet engraftment, but those with renal insufficiency had a transplantation-related mortality rate of 29% (four of 14). The 3-year overall survival rate was 56%, and the researchers concluded that renal insufficiency did not constitute a criterion for exclusion from transplantation.
Age and creatinine level did not have an effect on neutrophil engraftment. However, patients with impaired renal function needed a significantly longer time to achieve 50 000 platelets. Whether this difference (15 vs 18.5 days) has clinical significance is unknown (hemorrhagic complications were unusual in our patient group).
In conclusion, age does not appear to have an impact on day-100 mortality rate, time to progression, overall survival rate, engraftment rate or length of hospitalization. Appropriately selected patients over 65 years of age receiving high-dose therapy may have outcomes identical to that of a younger cohort. However, for patients with renal insufficiency, although the time to progression is identical, survival is inferior, time to platelet engraftment is significantly longer and the duration of hospital stays is nearly twice as long as that of patients with normal renal function. Moreover, because patients with renal insufficiency have a significantly higher therapy-related mortality rate, these factors must be considered when determining whether a patient with renal failure is suitable for high-dose therapy.
